

Bibliography

1. Meyer B. FDA "Black Box" Labeling. *Ann Emerg Med.* 2003 Apr; 41(4):55960
2. Lischke V, et al. Droperidol causes a dose-dependent prolongation of the QT interval. *Anesth Analg.* 1994; 79:983-986
3. Guy JM, et al. Torsades de pointes et allongement de la duree de l'intervalle QT apres injection de droperidol. *An de Cardiologie et d'Angeiologie.* 1991; 40:541-545
4. Reilly et al. QTc-interval abnormalities and psychotropic drug therapy in psychiatric patients. *Lancet* 2000; 355:1048--52
5. Lawrence & Nasraway, *Pharmacotherapy* 1997; 17(3): 531-7
6. Frye et al. Continuous droperidol infusion for management of agitated delirium in an intensive care unit. *Psychosomatics* 1995; 36:301-5
7. Drolet B et al. Droperidol lengthens cardiac repolarization due to block of the rapid component of the delayed rectifier potassium current. *J Cardiovas Electrophys* 1999; 10(12):1597--604
8. Michalets et a. Torsade de pointes resulting from the addition of droperidol to an existing cytochrome P450 drug interaction. *Ann Pharmacother* 1998; 32(7-8):761-5
9. Faigel et al. Torsade de pointes complicating the treatment of bleeding esophageal varices: association with neuroleptics, vasopressin, and electrolyte imbalance. *Am J Gastroenterol* 1995; 90(5):822-4
10. Roden D. Acquired long QT syndromes and the risk of proarrhythmia. *J Cardiovasc Electrophys* 2000; 11:938-40
11. Fenichel RR. Development of drugs that alter ventricular repolarization. *Am J Ther* 2002; 9(2):127-39
12. Malik M and Camm AJ. Evaluation of drug-induced QT interval prolongation. *Drug Safety* 2001; 24(5):323-351
13. Curran ME et al. Molecular mechanism of a serious adverse drug reaction: drug induced cardiac arrhythmias. *Pharm Disc Development*, 2002/03
14. Keating MT and Sanguinetti MC. Molecular and cellular mechanisms of cardiac arrhythmias. *Cell* 2001; 104:569-80